The fourth edition of PeptideWorld, Pep IQ's monthly news digest. Coverage window: 5 July → 24 August 2026. Regulation leads this month on both sides of the Atlantic, the two big obesity pipelines each had a mixed month, and enforcement caught up with the "research use only" market in a way it hadn't before. Scan the headlines, then expand each section. Every figure below is taken from the regulator, the company announcement or the meeting record — not from vendor blogs — and where we have only topline numbers rather than a peer-reviewed paper, we say so.
Headlines at a glance
-
Regulatory
The FDA panel voted for six of seven — against its own scientists' adviceOn 23–24 July the Pharmacy Compounding Advisory Committee recommended BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax for the 503A bulks list and rejected DSIP. Every vote was narrow, FDA staff had recommended against all seven, and a favourable vote is the start of rule-making, not the end. Seven Pep IQ entries updated.
-
UK regulatory
MHRA approves orforglipron — the first GLP-1 pill licensed in EuropeOn 10 August the MHRA authorised Foundayo for weight management and type 2 diabetes, four months after the FDA. It is prescription-only. Our entry and the oral GLP-1 protocol page both said "not yet UK-approved" — both now corrected, and the card strip moves from amber to POM.
-
Pipeline
Retatrutide: 28.3% at 80 weeks in TRIUMPH-1 — and the FDA filing slips to 2027Lilly's pivotal obesity trial reported in May; full data followed at ADA in June. The efficacy is the largest yet seen in a randomised obesity trial, tolerability still tracks dose, and the company has now pushed its US submission to the first quarter of 2027 for manufacturing data. Entry updated.
-
Pipeline
CagriSema missed non-inferiority against tirzepatide — a result we should have logged soonerREDEFINE 4 (reported February) put CagriSema at 23.0% against tirzepatide's 25.5% at 84 weeks and failed its primary endpoint. The FDA filing pre-dates that trial and a decision is still expected late 2026. Our entry carried a contradiction on filing status and called REDEFINE 2 "pending" — fixed.
-
Enforcement
A peptide vendor gets 70 months; the FDA moves on GLP-1 compounding; the UK lineThe first major criminal sentence in the "research use only" market, an FDA proposal to keep semaglutide, tirzepatide and liraglutide off the 503B outsourcing list, and MHRA activity around retatrutide grey supply. None of it changes the UK position — but all of it changes the odds for anyone buying blind.
Six of seven recommended — by the thinnest of margins
The vote we flagged as "days away" last issue has happened, and the outcome surprised the room. Over two days the FDA's Pharmacy Compounding Advisory Committee recommended that BPC-157, KPV, TB-500 and MOTS-c (day one) and Epitalon and Semax (day two) be added to the Section 503A bulks list. The one rejection was DSIP (emideltide), which went down 7–6 with an abstention. The first-day votes were 8–6 with one abstention for BPC-157, KPV and TB-500, and 7–5 with two abstentions for MOTS-c.
What makes this unusual is that the FDA's own reviewers had recommended against all seven, citing short, underpowered studies that could not establish safety or efficacy for the proposed uses — ulcerative colitis for BPC-157, wound healing for KPV and TB-500, obesity and osteoporosis for MOTS-c, insomnia for Epitalon, neurological uses for Semax. Advisory panels rarely vote against the agency's written position. This one was also newly reconstituted, with more clinicians and industry figures who prescribe or sell peptides, and that composition drew conflict-of-interest scrutiny during the meeting.
Now the part the celebratory coverage skips. Nothing is legal to compound today that wasn't legal on 22 July. The committee advises; the FDA decides, and it is not bound by the vote. To add a substance to the list the agency has to issue a proposed rule, take comment and publish a final rule — a process that has historically taken a year or more, and one the agency could still conclude in the negative. None of the six is FDA-approved and none has a USP monograph. We've updated all seven entries to read "PCAC voted for/against 503A listing" with the advisory caveat, and left the strips exactly where they were.
- Whether the FDA opens rule-making at all, and on which of the six — it can split them
- The next PCAC batch: LL-37, GHK-Cu, dihexa and Melanotan II are queued for review, with our entries already carrying the "by Feb 2027" marker
- UK effect: zero. A US compounding list changes nothing about MHRA licensing or what a UK vendor can lawfully sell for human use
The first GLP-1 pill licensed in Europe is a UK licence
On 10 August 2026 the MHRA authorised orforglipron (Foundayo, Eli Lilly) — the first regulator in Europe to do so, and four months after the FDA. The UK licence covers weight loss and weight maintenance in adults with a BMI of 30 or above, or 27–30 with at least one weight-related comorbidity, alongside a reduced-calorie diet and increased activity; and, separately, improving glycaemic control in type 2 diabetes that is insufficiently controlled. It is a prescription-only medicine, and the MHRA has said it will keep safety under close review, as it does for the whole GLP-1 class.
This is the correction we most needed to make. Last issue's headline story, and our orforglipron entry, were written around "FDA-approved, not yet UK-approved" — six separate lines in the entry, the oral GLP-1 protocol page and the card strip on the platform all said it. All of that is now updated: the strip moves from amber "not yet approved" to the same POM strip semaglutide and tirzepatide carry, and the entry now describes a licensed UK medicine with a licensed UK route. What has not changed is the boxed thyroid C-cell warning, the MTC/MEN-2 contraindication, or our position that a pill you can't verify is easier to counterfeit than an injection.
- UK availability and price — a licence is not a supply date, and the SmPC publishes within a week of approval
- NICE: whether and how it is appraised for NHS use, which is a separate process from licensing
- EMA: the EU route is still open and separate — "approved in the UK" does not mean approved in Ireland or Spain
The biggest number ever recorded in an obesity trial — and a later filing date
Our retatrutide entry stopped at TRIUMPH-4 (December 2025). It now carries the pivotal readout. On 21 May Lilly reported topline results from TRIUMPH-1, the 80-week obesity master trial in adults without diabetes: mean weight loss of 19.0% at 4 mg, 25.9% at 9 mg and 28.3% at 12 mg, against 2.2% on placebo. On the top dose 45.3% of participants lost 30% or more of their body weight — a threshold usually associated with bariatric surgery — and participants with a baseline BMI of 35 or above who continued into a blinded extension reached 30.3% at 104 weeks. Full data were presented at the American Diabetes Association meeting in June; TRIUMPH-2 (obesity with type 2 diabetes) and TRIUMPH-3 (established cardiovascular disease) are still to report this year.
Two honest caveats. First, tolerability still tracks dose. Discontinuation for adverse events rose with dose in TRIUMPH-1, and early reporting put the 12 mg rate below TRIUMPH-4's 18.2%, and it noted dysesthesia — abnormal skin sensation — as a distinct adverse event, mostly mild, with most affected participants continuing. We have not yet verified the per-arm figures against a peer-reviewed publication, and the entry says so. Second, the timeline moved the other way: Lilly had listed retatrutide among submissions expected by the end of 2026 but told CNBC in July that the FDA application is now planned for the first quarter of 2027, because it needs more time to assemble manufacturing and quality-control data. That pushes realistic approval into 2027–28.
- The NEJM publication of TRIUMPH-1 — the point at which discontinuation and dysesthesia rates become citable rather than topline
- TRIUMPH-2 and TRIUMPH-3 readouts in the second half of 2026
- The grey market: a compound with no approved product anywhere is being sold as a "research peptide" at scale, and regulators have noticed (see story 05)
A negative head-to-head we should have logged in February
This one is a correction as much as news. On 23 February 2026 Novo Nordisk reported REDEFINE 4, an 84-week open-label trial of CagriSema (cagrilintide 2.4 mg + semaglutide 2.4 mg) against tirzepatide 15 mg in 809 adults with obesity. CagriSema produced 23.0% weight loss assuming full adherence, versus 25.5% for tirzepatide; on the treatment-regimen estimand the figures were 20.2% and 23.6%. The trial did not meet its primary endpoint of non-inferiority. Novo's chief scientific officer attributed the miss to tirzepatide performing more strongly than expected, and the share price fell about 16% on the day.
Our entry didn't have it, and it also contradicted itself — "NDA filed" in one place, "NDA submission anticipated" in another — and described the REDEFINE 2 diabetes trial as pending when it reported 15.7% at 68 weeks long ago. All fixed. For the record: the US filing was made on 18 December 2025 on REDEFINE 1 and 2, so it pre-dates this head-to-head; a decision is still expected by late 2026. Novo is running REDEFINE 11 (readout first half 2027) and starting a higher-dose CagriSema trial in the second half of this year to find the ceiling. Pep IQ's position hasn't moved: a negative result belongs on the page, and approval-pending means not for community use.
- The FDA decision window — a miss against a competitor does not, by itself, block a placebo-controlled approval
- Whether the higher-dose programme closes the gap to tirzepatide and retatrutide
- An MHRA filing — none announced; "would be POM once approved" stays on the entry
The "research use only" market met a criminal court
On 3 August a US federal judge sentenced the owner of a peptide company to 70 months in prison after guilty pleas to selling unapproved drugs, unlawful importation and misleading customers about safety and origin. Prosecutors said products were marketed as high-purity, US-made research material on the strength of forged certificates of analysis; some were adulterated with testosterone, and one customer's steroid-induced psychosis featured in the sentencing. The judge described a trail of harm running through thousands of customers. It is one of the first serious criminal outcomes in a market that has mostly attracted warning letters, and it lands the point this site keeps making: a certificate of analysis is only worth the lab that issued it.
Two quieter moves in the same direction. On 30 April the FDA proposed formally excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list — the route outsourcing facilities used to mass-produce "compounded" GLP-1s during the shortages — on the basis that there is no clinical need now the approved products are available; the comment period closed in June. And in the UK, a summer of press attention on grey-market retatrutide brought MHRA investigations into clinics making therapeutic claims about unlicensed peptide products, alongside a sharp rise in US poison-centre exposures for the same compound.
- Approved abroad ≠ approved here — but this month, for orforglipron, it now is approved here. Check MHRA status, not headlines
- A US advisory vote does not make BPC-157 or TB-500 a medicine anywhere; they remain unlicensed, research-use only in the UK
- For the metabolic drugs, the prescribed route is the one with the safety record, the pharmacovigilance and the recall mechanism
- For everything sold as a research compound, sourcing risk sits with the buyer — and a forged CoA looks identical to a real one